Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01777412 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01777412: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT01777412 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01777412, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a phase 1b interventional trial of bevacizumab (Avastin®) to evaluate the tolerability/safety and preliminary efficacy of bevacizumab (Avastin®) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). A single infusion of Avastin® is added to standard-of-care high dose steroids and an additional dose of Avastin® is added to plasma exchange (if necessary). The primary outcomes are clinical changes in the Expanded Disability Severity Scale, Timed 25-foot Walk and Low Contrast Visual Acuity, MRI parameters and safety.
Interventions
- DRUG Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01777412
The ClinicalTrials.gov registry entry for NCT01777412 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab is the first listed.
NCT01777412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01777412 about?
NCT01777412 is a clinical study titled "Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations". This is a phase 1b interventional trial of bevacizumab (Avastin®) to evaluate the tolerability/safety and preliminary efficacy of bevacizumab (Avastin®) as add-on therapy for treatment of acute optic neuritis and/or transverse myelitis in neuromyelitis optica (NMO) and neuromyelitis optica spectrum ...
What is the current status of trial NCT01777412?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-06. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01777412?
The interventions under investigation include: Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01777412?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.